Tus Pharmaceutical Group Co Ltd (000590) - Net Assets
Based on the latest financial reports, Tus Pharmaceutical Group Co Ltd (000590) has net assets worth CN¥542.39 Million CNY (≈ $79.37 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥875.56 Million ≈ $128.12 Million USD) and total liabilities (CN¥333.17 Million ≈ $48.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Tus Pharmaceutical Group Co Ltd's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥542.39 Million |
| % of Total Assets | 61.95% |
| Annual Growth Rate | 7.36% |
| 5-Year Change | -19.47% |
| 10-Year Change | 108.17% |
| Growth Volatility | 35.82 |
Tus Pharmaceutical Group Co Ltd - Net Assets Trend (1995–2025)
This chart illustrates how Tus Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Tus Pharmaceutical Group Co Ltd to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Tus Pharmaceutical Group Co Ltd (1995–2025)
The table below shows the annual net assets of Tus Pharmaceutical Group Co Ltd from 1995 to 2025. For live valuation and market cap data, see Tus Pharmaceutical Group Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥549.49 Million ≈ $80.41 Million |
-8.61% |
| 2024-12-31 | CN¥601.23 Million ≈ $87.98 Million |
-17.44% |
| 2023-12-31 | CN¥728.20 Million ≈ $106.56 Million |
+3.66% |
| 2022-12-31 | CN¥702.49 Million ≈ $102.80 Million |
+2.96% |
| 2021-12-31 | CN¥682.32 Million ≈ $99.85 Million |
+5.81% |
| 2020-12-31 | CN¥644.88 Million ≈ $94.37 Million |
+3.65% |
| 2019-12-31 | CN¥622.16 Million ≈ $91.04 Million |
+7.32% |
| 2018-12-31 | CN¥579.72 Million ≈ $84.83 Million |
-0.62% |
| 2017-12-31 | CN¥583.33 Million ≈ $85.36 Million |
+121.00% |
| 2016-12-31 | CN¥263.96 Million ≈ $38.63 Million |
+28.26% |
| 2015-12-31 | CN¥205.79 Million ≈ $30.11 Million |
+11.78% |
| 2014-12-31 | CN¥184.11 Million ≈ $26.94 Million |
-31.69% |
| 2013-12-31 | CN¥269.51 Million ≈ $39.44 Million |
-43.69% |
| 2012-12-31 | CN¥478.58 Million ≈ $70.03 Million |
+36.41% |
| 2011-12-31 | CN¥350.83 Million ≈ $51.34 Million |
+25.80% |
| 2010-12-31 | CN¥278.88 Million ≈ $40.81 Million |
+20.61% |
| 2009-12-31 | CN¥231.22 Million ≈ $33.84 Million |
-28.36% |
| 2008-12-31 | CN¥322.78 Million ≈ $47.23 Million |
+5.07% |
| 2007-12-31 | CN¥307.22 Million ≈ $44.96 Million |
+13.26% |
| 2006-12-31 | CN¥271.26 Million ≈ $39.69 Million |
+1.01% |
| 2005-12-31 | CN¥268.54 Million ≈ $39.30 Million |
+0.36% |
| 2004-12-31 | CN¥267.57 Million ≈ $39.15 Million |
+3.24% |
| 2003-12-31 | CN¥259.16 Million ≈ $37.92 Million |
-7.74% |
| 2002-12-31 | CN¥280.91 Million ≈ $41.11 Million |
+0.81% |
| 2001-12-31 | CN¥278.65 Million ≈ $40.78 Million |
-26.67% |
| 2000-12-31 | CN¥380.02 Million ≈ $55.61 Million |
+9.26% |
| 1999-12-31 | CN¥347.80 Million ≈ $50.89 Million |
+29.40% |
| 1998-12-31 | CN¥268.78 Million ≈ $39.33 Million |
+11.57% |
| 1997-12-31 | CN¥240.92 Million ≈ $35.25 Million |
+69.77% |
| 1996-12-31 | CN¥141.91 Million ≈ $20.77 Million |
+117.26% |
| 1995-12-31 | CN¥65.32 Million ≈ $9.56 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tus Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 96501.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥759.32 Million | 138.66% |
| Total Equity | CN¥547.61 Million | 100.00% |
Tus Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Tus Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ld Intelligent Technology Co Ltd
SHE:300883
|
$319.99 Million |
|
Unitech Computer Co Ltd
TW:2414
|
$320.00 Million |
|
Steelcast Limited
NSE:STEELCAS
|
$320.01 Million |
|
JTL Industries Ltd
NSE:JTLIND
|
$320.02 Million |
|
Rotshtein
TA:ROTS
|
$319.88 Million |
|
Materialise NV
NASDAQ:MTLS
|
$319.66 Million |
|
Rossari Biotech Limited
NSE:ROSSARI
|
$319.65 Million |
|
Shenzhen Ecobeauty Co Ltd
SHE:000010
|
$319.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tus Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 598,246,119 to 547,612,827, a change of -50,633,292 (-8.5%).
- Net loss of 50,516,759 reduced equity.
- Dividend payments of 3,352,684 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-50.52 Million | -9.22% |
| Dividends Paid | CN¥3.35 Million | -0.61% |
| Other Changes | CN¥3.24 Million | +0.59% |
| Total Change | CN¥- | -8.46% |
Book Value vs Market Value Analysis
This analysis compares Tus Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 31.20x to 3.99x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | CN¥0.29 | CN¥9.13 | x |
| 1996-12-31 | CN¥0.64 | CN¥9.13 | x |
| 1997-12-31 | CN¥1.08 | CN¥9.13 | x |
| 1998-12-31 | CN¥1.20 | CN¥9.13 | x |
| 1999-12-31 | CN¥1.56 | CN¥9.13 | x |
| 2000-12-31 | CN¥1.68 | CN¥9.13 | x |
| 2001-12-31 | CN¥1.25 | CN¥9.13 | x |
| 2002-12-31 | CN¥1.27 | CN¥9.13 | x |
| 2003-12-31 | CN¥1.16 | CN¥9.13 | x |
| 2004-12-31 | CN¥1.20 | CN¥9.13 | x |
| 2005-12-31 | CN¥1.21 | CN¥9.13 | x |
| 2006-12-31 | CN¥1.21 | CN¥9.13 | x |
| 2007-12-31 | CN¥1.36 | CN¥9.13 | x |
| 2008-12-31 | CN¥1.45 | CN¥9.13 | x |
| 2009-12-31 | CN¥1.04 | CN¥9.13 | x |
| 2010-12-31 | CN¥1.30 | CN¥9.13 | x |
| 2011-12-31 | CN¥1.62 | CN¥9.13 | x |
| 2012-12-31 | CN¥2.14 | CN¥9.13 | x |
| 2013-12-31 | CN¥1.21 | CN¥9.13 | x |
| 2014-12-31 | CN¥0.82 | CN¥9.13 | x |
| 2015-12-31 | CN¥0.92 | CN¥9.13 | x |
| 2016-12-31 | CN¥1.17 | CN¥9.13 | x |
| 2017-12-31 | CN¥2.51 | CN¥9.13 | x |
| 2018-12-31 | CN¥2.42 | CN¥9.13 | x |
| 2019-12-31 | CN¥2.60 | CN¥9.13 | x |
| 2020-12-31 | CN¥2.69 | CN¥9.13 | x |
| 2021-12-31 | CN¥2.84 | CN¥9.13 | x |
| 2022-12-31 | CN¥2.92 | CN¥9.13 | x |
| 2023-12-31 | CN¥3.02 | CN¥9.13 | x |
| 2024-12-31 | CN¥2.50 | CN¥9.13 | x |
| 2025-12-31 | CN¥2.29 | CN¥9.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tus Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.96%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.62x
- Recent ROE (-9.22%) is below the historical average (-0.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 20.59% | 14.33% | 0.67x | 2.16x | CN¥6.92 Million |
| 1996 | 11.01% | 22.63% | 0.37x | 1.32x | CN¥1.44 Million |
| 1997 | 10.02% | 18.02% | 0.36x | 1.55x | CN¥41.23K |
| 1998 | 10.37% | 14.05% | 0.49x | 1.50x | CN¥986.96K |
| 1999 | 3.59% | 5.67% | 0.37x | 1.72x | CN¥-22.26 Million |
| 2000 | 8.08% | 10.70% | 0.45x | 1.70x | CN¥-7.20 Million |
| 2001 | -21.32% | -24.29% | 0.35x | 2.48x | CN¥-87.66 Million |
| 2002 | 1.44% | 1.38% | 0.41x | 2.55x | CN¥-24.29 Million |
| 2003 | -10.15% | -11.02% | 0.35x | 2.65x | CN¥-52.08 Million |
| 2004 | 2.03% | 2.03% | 0.39x | 2.53x | CN¥-21.32 Million |
| 2005 | 1.59% | 1.58% | 0.41x | 2.47x | CN¥-22.63 Million |
| 2006 | 1.07% | 1.01% | 0.53x | 2.01x | CN¥-24.24 Million |
| 2007 | 6.68% | 9.87% | 0.38x | 1.79x | CN¥-10.20 Million |
| 2008 | 6.31% | 8.61% | 0.41x | 1.77x | CN¥-11.90 Million |
| 2009 | -38.13% | -32.17% | 0.53x | 2.23x | CN¥-111.29 Million |
| 2010 | 16.30% | 15.13% | 0.55x | 1.97x | CN¥18.22 Million |
| 2011 | 19.97% | 21.00% | 0.57x | 1.67x | CN¥36.01 Million |
| 2012 | 28.75% | 37.86% | 0.52x | 1.47x | CN¥89.75 Million |
| 2013 | -61.02% | -64.24% | 0.46x | 2.05x | CN¥-191.40 Million |
| 2014 | -46.59% | -42.23% | 0.35x | 3.19x | CN¥-104.18 Million |
| 2015 | 10.87% | 7.59% | 0.50x | 2.85x | CN¥1.79 Million |
| 2016 | 21.14% | 18.30% | 0.48x | 2.42x | CN¥29.08 Million |
| 2017 | 3.29% | 6.55% | 0.34x | 1.50x | CN¥-39.16 Million |
| 2018 | -6.59% | -20.55% | 0.23x | 1.41x | CN¥-96.15 Million |
| 2019 | 6.82% | 13.47% | 0.37x | 1.36x | CN¥-19.77 Million |
| 2020 | 3.52% | 8.26% | 0.31x | 1.38x | CN¥-41.77 Million |
| 2021 | 5.21% | 11.78% | 0.31x | 1.42x | CN¥-32.59 Million |
| 2022 | 2.59% | 5.17% | 0.30x | 1.67x | CN¥-51.74 Million |
| 2023 | 3.49% | 6.24% | 0.35x | 1.59x | CN¥-47.12 Million |
| 2024 | -20.97% | -36.56% | 0.34x | 1.69x | CN¥-185.30 Million |
| 2025 | -9.22% | -14.96% | 0.38x | 1.62x | CN¥-105.28 Million |
Industry Comparison
This section compares Tus Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,002,519,147
- Average return on equity (ROE) among peers: 3.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tus Pharmaceutical Group Co Ltd (000590) | CN¥542.39 Million | 20.59% | 0.61x | $319.94 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Tus Pharmaceutical Group Co Ltd
Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food under the Guhan brand in China. It operates through the Pharmaceutical and Health Product Manufacturing and Sales Business, Active Pharmaceutical Ingredient (API) Manufacturing and Sales Business, and Other Business segments. The company offer… Read more